Huahai Pharmaceutical (600521.SH): New indications for the HB0056 injection project were approved for drug clinical trials

Zhitongcaijing · 1d ago

Zhitong Finance App News, Huahai Pharmaceutical (600521.SH) issued an announcement. Recently, the company's subsidiaries Shanghai Huaotai Biopharmaceutical Co., Ltd. (hereinafter referred to as “Huaotai”) and Huabo Biomedical Technology (Shanghai) Co., Ltd. (hereinafter referred to as “Huabo Biotech”, a wholly-owned subsidiary of Huaotai) received the “Drug Clinical Trial Approval Notice” approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) for the new indications of the HB0056 injection project.

The company's self-developed HB0056 is a bispecific antibody targeting TSLP and IL-11. Among them, TSLP is mainly involved in airway inflammation, and IL-11 is closely related to fibroblast activation and tissue remodeling. By simultaneously blocking the two signaling pathways, HB0056 is expected to inhibit airway inflammation while interfering with tissue remodeling to provide differentiated treatment strategies for COPD. Compared with existing single-target biologics, HB0056 has innovative advantages in dual-channel intervention mechanisms and potential clinical application value. Currently, two targeted biologics targeting specific groups of COPD patients have been approved for marketing in China, including Sanofi/regenerant IL-4Rα monoclonal antibody priumab approved in 2024 and GlaxoSmithK.com's IL-5 monoclonal antibody Mepolizumab approved in 2025, marking the gradual development of COPD treatment towards precise targeted treatment.